Cholestasis Clinical Trial
Official title:
Cholestasis Prevention: Efficacy of IV Fish Oil
Verified date | December 2020 |
Source | Boston Children's Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Parenteral nutrition (PN) solutions are life saving in patients with surgical gastrointestinal diseases. However, the use of PN in pediatric populations, especially premature infants, is frequently associated with liver injury that may ultimately result in hepatic failure. In studies conducted in a murine model, we observed that intravenous fat emulsions (IFE) comprised of omega-3 fatty acids were able to prevent the development of cholestasis, a common precursor of PN-associated liver disease, as well as reverse preexisting PNALD through a combination of factors, including improved triglyceride clearance coupled with anti-inflammatory properties. In a case series treating patients with hepatic cholestasis, serum bilirubin levels decreased markedly after the parenteral administration of an omega-3 fatty acid based fat emulsion (Omegaven®). Patients tolerated this therapy and no adverse reactions attributed to its use were observed. Based on results of these previous studies, we propose to conduct a randomized trial aiming to gain preliminary evidence of efficacy of an omega-3 fatty acid based IFE in preventing PNALD in children with intestinal failure
Status | Completed |
Enrollment | 19 |
Est. completion date | December 2011 |
Est. primary completion date | December 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 3 Months |
Eligibility | Inclusion criteria (all of the following): 1. Congenital or acquired gastrointestinal disease requiring surgical intervention [such as Midgut volvulus, Gastroschisis-(with known or suspected atresia(s), perforation(s) requiring a jejunostomy, or bowel resections > 20cm), Omphalocele, Jejunal atresia or NEC-(no peritoneal drains) or duodenal atresia] ; and 2. Expected dependence on parenteral nutrition for full or partial nutritional support for an anticipated duration of therapy of at least 21 days; Subjects will be judged by their clinical team to require PN support a minimum of 21 days based on the following criteria: inability to tolerate enteral feedings, lack of audible bowel sounds, contraindications to initiation of enteral feedings (e.g., grossly bloody stools or other sign of intestinal ischemia, hypotension, bilious emesis, or clinical or radiographic evidence of bowel obstruction); and 3. Neonates and infants < 3 months of age (postnatally); and 4. Gestational age > 28 weeks; and 5. Baseline direct bilirubin less than 1.0 mg/dL (normal); and 6. Weight > 1 kg Exclusion criteria(any one of the following): 1. Exposure to soybean oil fat emulsion for greater than three weeks (>21 days) at time of enrollment 2. Known or suspected intolerance or allergy to any of the components of the study IFE, including fish, soy or egg protein 3. Inability to obtain written informed consent prior to the baseline labs 4. The patient is enrolled in any other clinical trial involving an investigational agent (unless approved by the designated physicians on the multidisciplinary team) 5. Intention to transfer care to another patient facility within 3 months of baseline labs 6. Any serum triglyceride level greater than 400 mg/dL at baseline 7. History of severe hemolytic disorders or INR greater than 1.5 at baseline (INR cutoff of greater than 2 for babies less than 1 week of age) 8. History of shock requiring vasopressors (dopamine equal or less than 20 micrograms/kilogram/minute is allowed; all other use of vasopressors is excluded) 9. Preexisting liver disease, regardless of etiology 10. Hemodynamically unstable as judged by PI 11. Renal failure (creatinine greater than 0.4 mg/dL unless less than 1 month of age-then at the PI's discretion) 12. Patient previously had STEP (Serial Transverse Enteroplasty Procedure) 13. Patient is currently on ECMO or nitric oxide 14. GGTP > 80 mg/L at baseline 15. Weight < 1 kg at time of enrollment 16. Gestational age < 28 weeks at time of enrollment |
Country | Name | City | State |
---|---|---|---|
United States | Childrens's Hospital Boston | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Boston Children's Hospital |
United States,
Nehra D, Fallon EM, Potemkin AK, Voss SD, Mitchell PD, Valim C, Belfort MB, Bellinger DC, Duggan C, Gura KM, Puder M. A comparison of 2 intravenous lipid emulsions: interim analysis of a randomized controlled trial. JPEN J Parenter Enteral Nutr. 2014 Aug; — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Presence vs. absence of PN-associated cholestasis (PNAC) | The definition of "Presence vs. Absence of PNAC" will vary with the post conceptual age of the child. In infants > 40 weeks post conceptual age, we will define PN-associated cholestasis as four consecutive measurements (> 6 days apart) of serum direct bilirubin > 2.0mg/dL obtained over a 30 day period in the absence of other demonstrable etiologies of cholestasis. Due to hepatic immaturity, for infants < 40 weeks post conceptual age, PN associated cholestasis will be defined as four consecutive measurements (> 6 days apart) of serum direct bilirubin > 2.0mg/dL obtained over a 42 day period. | 6 months | |
Secondary | Fatty acid profiles | (i.e., Mead acid levels, triene:tetraene ratios, total omega-3 and omega-6 fatty acid levels, arachidonic acid levels) | 6 months | |
Secondary | Weight and height gain | 6 months | ||
Secondary | Liver function tests | (i.e. serum triglycerides, cholesterol, ALT, AST and total and direct bilirubin levels) | 6 months | |
Secondary | Death from PNALD liver or liver/gastrointestinal tract transplant. | 1 year | ||
Secondary | Duration of parenteral nutrition | (i.e. enteral feeding tolerance, including days to reach full enteral feeding (approximately 100-125kcal/kg/d + 10%) after randomization and the number of episodes of feeding intolerance (defined as an interruption of enteral feedings for > 12 hrs) , number of infants requiring TPN providing > 10% of total daily fluid volume at 12 weeks after randomization, and duration of TPN providing > 10% of total daily fluid intake) | 6 months | |
Secondary | Frequency of blood stream infections | 6 months | ||
Secondary | Inflammatory markers (C-reactive protein), cytokine levels | 6 months | ||
Secondary | Incidence and severity of ROP | 6 months | ||
Secondary | Neurodevelopment Assessments | Neurodevelopment will be assessed at 6, 12, and 24 months (corrected) using Bayley Scales of Infant Development III(mean total, cognitive, language, and motor scaled score; and frequency of each score <70). The MSD parent questionnaire will be mailed at 12 and 24 months (corrected); and the Parent Report of Children's Abilities - Revised (PARCA-R) parent questionnaire will be mailed at 24 months (coorected). | 6, 12, & 24 months (corrected for gestational age) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04510090 -
Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
|
Phase 1 | |
Completed |
NCT02917408 -
Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
|
||
Completed |
NCT00738101 -
Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants
|
N/A | |
Completed |
NCT00004414 -
Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis
|
N/A | |
Completed |
NCT03662282 -
Omegaven as Alternative Parenteral Fat Nutrition
|
Phase 3 | |
Recruiting |
NCT02334293 -
Omegaven® as Parenteral Nutrition
|
N/A | |
Recruiting |
NCT01252043 -
Retrospective Review of CT and MR in Pediatric Patients With Cholestasis
|
N/A | |
Completed |
NCT00846963 -
Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates
|
Phase 2/Phase 3 | |
Completed |
NCT00007033 -
Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease
|
N/A | |
Completed |
NCT01194063 -
Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children
|
Phase 3 | |
Recruiting |
NCT01998620 -
Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis
|
Phase 4 | |
Completed |
NCT00080236 -
Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation
|
Phase 2 | |
Completed |
NCT00058890 -
Gabapentin to Treat Itch in Patients With Liver Disease
|
Phase 3 | |
Active, not recruiting |
NCT00004315 -
Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease
|
Phase 2 | |
Active, not recruiting |
NCT02922751 -
FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
|
||
Completed |
NCT04604652 -
Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis
|
Phase 2 | |
Terminated |
NCT02267707 -
Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia
|
Phase 1 | |
Completed |
NCT02357576 -
Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD
|
Phase 3 | |
Completed |
NCT02721277 -
SMOFlipid to Lessen the Severity of Neonatal Cholestasis
|
Phase 1/Phase 2 | |
Terminated |
NCT02767648 -
Inter-regional Cohort of Neonatal and Infant Cholestasis in the Greater Southwest Region
|
N/A |